-DOCSTART- -X- O
Severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
highly -X- _ O
lethal -X- _ O
emerging -X- _ O
disease -X- _ O
caused -X- _ O
by -X- _ O
coronavirus -X- _ O
SARS-CoV. -X- _ O
New -X- _ O
lethal -X- _ O
animal -X- _ O
models -X- _ O
for -X- _ O
SARS -X- _ O
were -X- _ O
needed -X- _ O
to -X- _ O
facilitate -X- _ O
antiviral -X- _ B-Intervention
research. -X- _ I-Intervention
We -X- _ O
adapted -X- _ O
and -X- _ O
characterized -X- _ O
a -X- _ O
new -X- _ O
strain -X- _ O
of -X- _ O
SARS-CoV -X- _ O
( -X- _ O
strain -X- _ O
v2163 -X- _ O
) -X- _ O
that -X- _ O
was -X- _ O
highly -X- _ O
lethal -X- _ O
in -X- _ O
5–6 -X- _ B-Patient
week -X- _ I-Patient
old -X- _ I-Patient
BALB -X- _ I-Patient
/ -X- _ I-Patient
c -X- _ I-Patient
mice. -X- _ I-Patient
It -X- _ O
had -X- _ O
nine -X- _ O
mutations -X- _ O
affecting -X- _ O
10 -X- _ O
amino -X- _ O
acid -X- _ O
residues. -X- _ O
Strain -X- _ B-Outcome
v2163 -X- _ I-Outcome
increased -X- _ I-Outcome
IL-1α -X- _ I-Outcome
, -X- _ I-Outcome
IL-6 -X- _ I-Outcome
, -X- _ I-Outcome
MIP-1α -X- _ I-Outcome
, -X- _ I-Outcome
MCP-1 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
RANTES -X- _ I-Outcome
in -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
high -X- _ I-Outcome
IL-6 -X- _ I-Outcome
expression -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
mortality. -X- _ I-Outcome
The -X- _ O
infection -X- _ O
largely -X- _ O
mimicked -X- _ O
human -X- _ O
disease -X- _ O
, -X- _ O
but -X- _ O
lung -X- _ B-Outcome
pathology -X- _ I-Outcome
lacked -X- _ I-Outcome
hyaline -X- _ I-Outcome
membrane -X- _ I-Outcome
formation. -X- _ I-Outcome
In -X- _ I-Outcome
vitro -X- _ I-Outcome
efficacy -X- _ I-Outcome
against -X- _ I-Outcome
v2163 -X- _ I-Outcome
was -X- _ I-Outcome
shown -X- _ I-Outcome
with -X- _ I-Outcome
known -X- _ I-Outcome
inhihibitors -X- _ I-Outcome
of -X- _ I-Outcome
SARS-CoV -X- _ I-Outcome
replication. -X- _ I-Outcome
In -X- _ I-Outcome
v2163-infected -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
AmpligenTM -X- _ I-Outcome
was -X- _ I-Outcome
fully -X- _ I-Outcome
protective -X- _ I-Outcome
, -X- _ I-Outcome
stinging -X- _ I-Outcome
nettle -X- _ I-Outcome
lectin -X- _ I-Outcome
( -X- _ I-Outcome
UDA -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
partially -X- _ I-Outcome
protective -X- _ I-Outcome
, -X- _ I-Outcome
ribavirin -X- _ I-Outcome
was -X- _ I-Outcome
disputable -X- _ I-Outcome
and -X- _ I-Outcome
possibly -X- _ I-Outcome
exacerbated -X- _ I-Outcome
disease -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
EP128533 -X- _ I-Outcome
was -X- _ I-Outcome
inactive. -X- _ I-Outcome
Ribavirin -X- _ I-Outcome
, -X- _ I-Outcome
UDA -X- _ I-Outcome
and -X- _ I-Outcome
AmpligenTM -X- _ I-Outcome
decreased -X- _ I-Outcome
IL-6 -X- _ I-Outcome
expression. -X- _ I-Outcome
Strain -X- _ O
v2163 -X- _ O
provided -X- _ O
a -X- _ O
valuable -X- _ O
model -X- _ O
for -X- _ O
anti-SARS -X- _ O
research -X- _ O
. -X- _ O

